• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
SHI Qinqing, WANG Jinghua, CHENG Manman, YIN Lifang, QIN Chao. Preparation and in vitro release of ivabradine hydrochloride elementary osmotic pump tablets[J]. Journal of China Pharmaceutical University, 2021, 52(3): 311-317. DOI: 10.11665/j.issn.1000-5048.20210307
Citation: SHI Qinqing, WANG Jinghua, CHENG Manman, YIN Lifang, QIN Chao. Preparation and in vitro release of ivabradine hydrochloride elementary osmotic pump tablets[J]. Journal of China Pharmaceutical University, 2021, 52(3): 311-317. DOI: 10.11665/j.issn.1000-5048.20210307
shu

Preparation and in vitro release of ivabradine hydrochloride elementary osmotic pump tablets

  • Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China

Funds: This study was supported by the National Natural Science Foundation of China(No.81871477)
More Information
  • Received Date: January 05, 2021
  • Revised Date: May 11, 2021
    Graphical Abstract
    • Abstract
  • In this study, ivabradine hydrochloride (IVB) was prepared as elementary osmotic pump tablets whose administration frequency was reduced to once daily. The dissolution method was developed, and effects on drug release profiles were evaluated by single factor analysis involving suspending agents, osmotic active agents and aging process. Orthogonal test was carried out at 3 levels on 3 factors including the amount of polyoxyethylene (PEO) in the core, polyethylene glycol (PEG) percentage and weight increase of controlled-release film coatings. The final formulation consisted of IVB (16.25 mg), PEO N80 (60 mg), hypromellose E5 (10 mg), lactose (111.75 mg), magnesium stearate (2 mg); and the film coatings consisted of PEG (15%), cellulose acetate (85%), with a weight increase of 7.5%. In vitro drug release behaviors were investigated. Prepared tablets exhibited similar release profiles in different pH dissolution media, with no risk of dose dumping in 40% ethanol solutions. The osmotic pressure differences inside and outside the membrane drove drug release. IVB osmotic pump tablets could reduce the frequency of administration and improve patients'' compliance, thus with better application values.
    • FullText(HTML)
    • References (15)
  • [1]
    . Pharmacol Res，2006，53（5）：424-434.
    [2]
    Li JD，Gan T. The clinical application of If current inhibitor ivabradine［J］. J Clin Cardiol（临床心血管病杂志），2020，36（3）：212-214.
    [3]
    Electronic Medicines CompendiumUK.Summary of product characteristics of procoralan［EB/OL］.（2019-01-25）［2021-01-06］.https：//www.medicines.org.uk/emc/product/166/smpc.
    [4]
    Mullasari A，investigatorsPROFICIENT. Efficacy and safety of ivabradine once-daily prolonged-release versus twice-daily immediate-release formulation in patients with stable chronic heart failure with systolic dysfunction：a randomized，double-blind，phase 3 non-inferiority （PROFICIENT） study［J］. Cardiol Ther，2020，9（2）：505-521.
    [5]
    Xu X，Wei YL，Ji W，et al. Pharmacokinetic profile of ivabradine hemisulfate sustained-release tablets administered in Chinese healthy volunteers：an open-label，randomized，single-dose，three-period crossover study［J］. Biomed Chromatogr，2019，33（11）：e4662.
    [6]
    Ma L. Progress in osmotic pump drug delivery system［J］. J China Pharm Univ（中国药科大学学报），2014，45（6）：726-730.
    [7]
    Thombre AG，Appel LE，Chidlaw MB，et al. Osmotic drug delivery using swellable-core technology［J］. J Control Release，2004，94（1）：75-89.
    [8]
    Malaterre V，Ogorka J，Loggia N，et al. Oral osmotically driven systems：30 years of development and clinical use［J］. Eur J Pharm Biopharm，2009，73（3）：311-323.
    [9]
    Zhu L，Qin C，Wu JL，et al. Preparation and in vitro evaluation of pregabalin controlled porosity osmotic pump tablets［J］. J China Pharm Univ（中国药科大学学报），2019，50（1）：53-58.
    [10]
    Masciocchi N，Aulisio A，Bertolini G，et al. Disclosing the extensive crystal chemistry of Ivabradine hydrochloride，in its pure and solvated phases［J］. Powder Diffr，2013，28（3）：200-206.
    [11]
    Zhou XB，Zhu JR，Liu JY，et al. Crystal structures and properties of two hydrated conglomerate forms of the heart-rate-lowering agent ivabradine hydrochloride［J］. Acta Crystallogr C Struct Chem，2019，75（Pt 5）：545-553.
    [12]
    Waterman KC，MacDonald BC，Roy MC. Extrudable core system：development of a single-layer osmotic controlled-release tablet［J］. J Control Release，2009，134（3）：201-206.
    [13]
    Smith AP，Moore TW，Westenberger BJ，et al. In vitro dissolution of oral modified-release tablets and capsules in ethanolic media［J］. Int J Pharm，2010，398（1/2）：93-96.
    [14]
    Jedinger N，Khinast J，Roblegg E. The design of controlled-release formulations resistant to alcohol-induced dose dumping：a review［J］. Eur J Pharm Biopharm，2014，87（2）：217-226.
    [15]
    Costa P，Sousa Lobo JM. Modeling and comparison of dissolution profiles［J］. Eur J Pharm Sci，2001，13（2）：123-133.
    • Related Articles

  • Related Articles

    [1]YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
    [2]LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901
    [3]WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
    [4]YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003
    [5]ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403
    [6]LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
    [7]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [8]CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203
    [9]WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303
    [10]TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572.

  • Cited by

    Periodical cited type(9)

    1. 蔡鸿飞，张琴，关伟键，杨阳，袁诚，许文东. 不同干燥方式对灵芝孢子粉中灵芝孢子油过氧化值的影响. 广东化工. 2024(01): 28-30 .
    2. 林志彬. 灵芝孢子油的药效物质基础研究进展. 菌物研究. 2024(01): 79-87 .
    3. Jianying Liu，Binzhi Zhang，Leqi Wang，Shasha Li，Qinqiang Long，Xue Xiao. Bioactive components, pharmacological properties and underlying mechanism of Ganoderma lucidum spore oil: A review. Chinese Herbal Medicines. 2024(03): 375-391 .
    4. 武美华，张胜男，敬隆鑫，律凤霞. 灵芝的活性成分及其药理作用的研究进展. 中国林副特产. 2023(02): 76-79 .
    5. 夏凤娜，关小莺，陈少丹，陈秋颜，张一帆，杨小兵. 灵芝孢子粉脂质成分HPLC-ELSD指纹图谱构建及含量测定. 食用菌学报. 2023(06): 52-59 .
    6. 井子良，吴纯宇，张慧敏，孙建博. 灵芝孢子油番茄红素复合物的抗肿瘤作用. 现代食品科技. 2022(09): 46-51 .
    7. 李志强，何玉霞. 灵芝多糖对人肺癌A549细胞增殖凋亡的作用. 现代食品科技. 2021(05): 38-42 .
    8. 张琴，李康强，杨阳，张圳，蔡鸿飞，许文东. 不同提取方式的灵芝孢子油品质研究. 广东化工. 2021(11): 48-49 .
    9. 包县峰，徐勇，刘维明，王星丽，孙培龙，张安强. 灵芝孢子粉生物活性成分及药理作用. 食品工业科技. 2020(06): 325-331 .

    Other cited types(6)

Catalog

    Get Citation
    PDF
    XML
    Article views (190) PDF downloads (652) Cited by(15)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：286500

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return